On May 2, 2023, the U.S. FDA announced that it was taking additional steps to support the use of decentralized clinical trials (DCTs) for drugs, biologics and devices, where some or all the trial-related activities occur at locations other than traditional clinical trial sites.

Decentralizing clinical trials will allow some or all trial-related activities to take place at trial participantsﾒ homes or other convenient locations, instead of having them visit research sites.